|Bid||343.70 x 1000|
|Ask||345.00 x 800|
|Day's range||340.43 - 344.36|
|52-week range||268.62 - 372.61|
|Beta (3Y monthly)||1.27|
|PE ratio (TTM)||60.14|
|Earnings date||29 Jul 2019 - 2 Aug 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||345.71|
Illumina, Inc. (ILMN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
The Zacks Analyst Blog Highlights: American International, Arconic, Hasbro, Illumina and Jefferies
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank 2 (Buy) or better.
Next-generation Sequencing-based Solution Provides Accurate, Fast and Scalable End-to-end Genome-wide Noninvasive Prenatal Testing
Illumina, Inc. today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.
If you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Illumina (ILMN).
Illumina, Wix.com, Microsoft, Facebook and Oracle highlighted as Zacks Bull and Bear of the Day
Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.
These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.